Osteoprotegerin
Osteoprotegerin (OPG) belongs to the tumor necrosis factor receptor (TNFR) superfamily. Osteoprotegerin blocks the RANKL-RANK interaction as well as the binding of TRAIL to its receptor. Osteoprotegerin activates NF-κB to induce the expression of ICAM-1, VCAM-1 and E-selectin, and activates the phosphorylation of ERK1/2. Osteoprotegerin regulates osteoclast activity, inhibits osteoclast maturation and formation, bone lysis and bone resorption, and increases bone mass. Osteoprotegerin regulates vascular endothelial cell function. Osteoprotegerin can be used in the research of cardio-cerebrovascular and bone-related diseases.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 19220-35-0
- 화학식: C18H32O2
- 분자량:280.45
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
Biological Activity
제품 설명
In Vitro
Osteoprotegerin dose-dependently upregulates the expression of AT1 receptors in human vascular smooth muscle cells and cells derived from atherosclerotic plaques, and directly activates the phosphorylation of ERK1/2 in vitro[1].
Osteoprotegerin inhibits RANKL-induced matrix metalloproteinase activity in human vascular smooth muscle cells *in vitro* by sequestering RANKL and preventing its binding to RANK[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 19220-35-0
-
분자량 280.45
-
화학식 C18H32O2
-
SMILES
O=C(CCCCCC#CCCCCCCCCCC)O
-
Synonyms
OPG
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Dutka M, et al. Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart failure reviews. 2022 Jul;27(4):1395-1411. [Content Brief]
[2]. Payr S, et al. Direct comparison of 3D and 2D cultivation reveals higher osteogenic capacity of elderly osteoblasts in 3D. Journal of orthopaedic surgery and research. 2021 Jan 06;16(1):13. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Osteoprotegerin Related Classifications
HY-183516 Related Classifications
Powered by Bioz